Which U.S. healthcare company created the diabetes drug Mounjaro?

Eli Lilly created the diabetes drug Mounjaro.

Mounjaro is the brand name for tirzepatide, which the U.S. Food and Drug Administration approved in 2022 for improving blood-sugar control in adults with type 2 diabetes. Eli Lilly and Company developed and markets the medicine.

Tirzepatide acts on receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Its dual mechanism distinguishes it from medicines that target only one of those pathways. Eli Lilly later marketed tirzepatide for chronic weight management in the United States under the brand name Zepbound.

Mounjaro is often confused with Ozempic, which contains semaglutide and is made by Novo Nordisk. Both are injectable medicines used in diabetes care, but they contain different active ingredients and are made by different companies.